(Photo Courtesy: www.sodahead.com)
"We are in the process of responding to the allegation. Fortunately, the issue will not have any impact on the company. Out of the two products questioned, one of them (Divalproex Sodium) is not being marketed in the US by Dr Reddy's. The US is a highly litigious country which we call our ‘home market'. We need to get used to such allegations. We will cooperate with the US in all respect," said Mr Kedar Upadhye, VP & head, global generics finance and investor relations, Dr Reddy's Laboratories, speaking exclusively to BioSpectrum.
However, Sun Pharmaceuticals responded saying ‘No comments' for BioSpectrum's email query on the issue.
Similarly, Zydus Cadila didn't elicit any response to the email query as of on the evening of October 13, 2014.
Shares of Sun was trading at Rs 803.55 each, down by Rs 15.25 or 1.86 percent, and Dr Reddy's was trading at Rs 2947.20, down by Rs 52.75 or 1.76 percent.
Zydus Cadila was observed at Rs 1348.35, up by Rs 25.55 or 1.93 percent on October 13, 2014 on Bombay Stock Exchange (BSE) at 1640 hrs.